Codexis shares surge 12.77% intraday after signing evaluation agreement with Axolabs for oligonucleotide therapeutics.

Codexis Inc. surged 12.77% intraday after announcing an evaluation agreement with Axolabs to expand its ECO Synthesis® manufacturing platform for oligonucleotide therapeutics. This partnership, disclosed in a PR Newswire article, highlights Codexis’s strategic move to enter therapeutic siRNA manufacturing, a growing sector within synthetic biology. The deal underscores the company’s potential to leverage its technology in high-demand biopharmaceutical applications, likely boosting investor confidence. Earlier news, including Q3 earnings reports and lease agreements, did not align with the intraday rally, while the Axolabs collaboration represents a near-term catalyst for operational expansion and revenue potential.